Danger signals in tumor cells: A risk factor for autoimmune disease?

Expert Review of Vaccines

Volumn 9, Issue 4, 2010, Pages 347-350

  Schirrmacher, Volker ^a   Fournier, Philippe ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS TUMOR VACCINE; CANCER VACCINE; CD24 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAMAGE ASSOCIATED MOLECULAR PATTERN; DENDRITIC CELL VACCINE; NEWCASTLE DISEASE VACCINE; PATTERN RECOGNITION RECEPTOR; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GLIOMA; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION; LYMPHATIC SYSTEM DISEASE; MOLECULAR RECOGNITION; NEOPLASM; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR IMMUNITY; VASCULITIS; VIRUS CARCINOGENESIS; VIRUS REPLICATION; ANIMAL; AUTOIMMUNE DISEASES; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; CANCER VACCINES; HUMANS; NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 77950600175     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.15     Document Type: Editorial

References (35)

1. Gilboa E. The makings of a tumor rejection antigen. Immunity 11(3), 263-270 (1999). (Pubitemid 29463234)
2. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev. Vaccines 8(1), 51-66 (2009).
3. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994). (Pubitemid 24140436)
4. Medzhitov R, Janeway CA Jr. Innate immunity: The virtues of a nonclonal system of recognition. Cell 91, 295-298 (1997). (Pubitemid 27467959)
5. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7, 179-190 (2007). (Pubitemid 46310482)
6. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006). (Pubitemid 43261452)
7. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 296, 298-300 (2002). (Pubitemid 34303673)
8. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295-298 (1997). (Pubitemid 27467959)
9. Lotze MT, Zeh HJ, Rubartelli A et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev. 220, 60-81 (2007). (Pubitemid 350045579)
10. Seong SY, Matzinger P. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4(6), 469-478 (2004). (Pubitemid 38745558)
11. Seong SY. A missed proteome in living organisms: a Hyppo system. Curr. Proteome 3(2), 129-145 (2006).
12. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17, 359-365 (2005).
13. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, Horton MR. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 177, 1272-1281 (2006).
14. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999).
15. Roth J, Vogl T, Sorg C, Sunderkotter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol. 24, 155-158 (2003).
16. Fournier P, Zeng J, Schirrmacher V. Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-a responses by viral protein or dsRNA. Int. J. Oncol. 23(3), 673-680 (2003).
17. Fábián Z, Csatary CM, Szeberényi J, Csatary LK. p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J. Virol. 81(6), 2817-2830 (2007).
18. Schirrmacher V, Fournier P. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol. Biol. 542, 565-605 (2009).
19. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 58(1), 61-69 (2009).
20. Steiner HH, Bonsanto MM, Beckhove P et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol. 22(21), 4272-4281 (2004).
21. Karcher J, Dyckhoff G, Beckhove P et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 64(21), 8057-8061 (2004).
22. Ahlert T, Sauerbrei W, Bastert G et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J. Clin. Oncol. 15(4), 1354-1366 (1997).
23. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(1), 1-13 (1989).
24. Schirrmacher V, Ahlert T, Pröbstle T et al. Immunization with virus-modified tumor cells. Semin. Oncol. 25(6), 677-696 (1998).
25. Hemmi H, Akira S. TLR signalling and the function of dendritic cells. Chem. Immunol. Allergy 86, 120-135 (2005).
26. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
27. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323(5922), 1722-1725 (2009).
28. Li O, Chang X, Zhang H et al. Massive and destructive T cell response to homeostatic cue in CD24-deficient lymphopenic hosts. J. Exp. Med. 203(7), 1713-1720 (2006).
29. Liu Y, Zheng P. CD24: a genetic checkpoint in T-cell homeostasis and autoimmune diseases. Trends Immunol. 28(7), 315-320 (2007).
30. Maier T, Tun-Kyi A, Tassis A et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102(7), 2338-2344 (2003).
31. Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. 11(11), 4160-4167 (2005).
32. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61, 842-847 (2001).
33. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003).
34. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GMCSF)- producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
35. Kim J, Lahl K, Hori S et al. Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J. Immunol. 183(12), 7631-7634 (2009).